BMC Series blog
Fabian V. Filipp
Fabian V. Filipp is a professor for Systems Biology and Cancer Metabolism focused on the connection between epigenomic master regulators and their control over central metabolism as an opportunity for diagnosis and treatment of therapy-resistant cancers.
He completed his PhD at the European Molecular Biology Laboratory in Heidelberg, receives funding from National Institutes of Health, National Cancer Institute, National Science Foundation, European Molecular Biology Organization, and the University of California Cancer Research Coordinating Committee, and spearheads the cancer systems biology research group at the University of California Merced. He is an elected council member of the PanAmerican Society for Pigment Cell Research.
He completed his PhD at the European Molecular Biology Laboratory in Heidelberg, receives funding from National Institutes of Health, National Cancer Institute, National Science Foundation, European Molecular Biology Organization, and the University of California Cancer Research Coordinating Committee, and spearheads the cancer systems biology research group at the University of California Merced. He is an elected council member of the PanAmerican Society for Pigment Cell Research.
Systems biology study identifies acquired cancer resistance beyond mutations
Precision targeting offers hope after a life-changing cancer diagnosis. However, some cancers that initially respond to targeted chemotherapy become treatment-resistant — and this may have nothing to do with the drug itself. Hidden layers of regulation that control the activity of genes can produce drug-resistant, surviving cells. New research, published today in BMC Systems Biology helps explain how therapy-resistant cancers arise — findings with important implications for the future of cancer therapy.
No hay comentarios:
Publicar un comentario